Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Brief summary
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Detailed description
Currently, the R-CHOP regimen can cure approximately 60% of DLBCL patients. The Pola-R-CHP regimen has shown further improvement on this basis. However, from the POLARIX study, it was observed that patients under 60 years old, with an IPI score of 2, and those with large masses did not show further benefits from the Pola regimen. Meanwhile, for patients with poor prognosis such as non-GCB, there is still room for further improvement with the Pola-R-CHP regimen. BTK inhibitors have demonstrated ideal therapeutic effects for the aforementioned patient types, and currently, a large number of patients have been treated with this type of therapy in clinical practice. However, the vast majority have been combined with R-CHOP-like regimens. There are no data reported on the combination of BTK inhibitors with the Pola regimen. Therefore, this study plans to assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive non-GCB diffuse large B-cell lymphoma (DLBCL). Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
Interventions
DRUGorelabrutinib combined with the Pola-R-CHP regimen
Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
Sponsors
The Second Affiliated Hospital of Jiaxing University
Taizhou First People's Hospital
Huzhou Central Hospital
Zhejiang Cancer Hospital
Dongyang People's Hospital
Yuyao People's Hospital
Taizhou Hospital
Shaoxing Central Hospital
Affiliated Hospital of Jiaxing University
Shaoxing People's Hospital
The Central Hospital of Lishui City
Second Affiliated Hospital of Wenzhou Medical University
Ningbo People's Hospital
The People's Hospital of Quzhou
Zhuji People's hospital
Affiliated Hangzhou First People's Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18 to 80 years old. 2. Diffuse large B-cell lymphoma (DLBCL) confirmed by tumor tissue pathology, with at least one measurable lesion. 3. Non-GCB. 4. No prior anti-tumor treatment. 5. ECOG score of 0-2. 6. Life expectancy of ≥6 months. 7. Voluntary written informed consent.
Exclusion criteria
1. Lymphoma involving the central nervous system or leptomeningeal metastasis. 2. Transformed lymphoma, that is, transformed from other types of lymphoma, such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or small B-cell lymphoma. 3. Primary mediastinal large B-cell lymphoma. 4. Burkitt lymphoma. 5. Laboratory values at screening (unless due to lymphoma): 1. Neutrophils \<1.5×10⁹/L; 2. Platelets \<75×10⁹/L; 3. ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal; 4. Creatinine level more than 1.5 times the upper limit of normal. 6. Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol. 7. Pregnant or breastfeeding women. 8. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (positive result by polymerase chain reaction \[PCR\]). If the patient tests positive for HbsAg, HBV DNA testing is required. If HBV DNA \<10³ IU/ml, the patient may be enrolled. If the patient tests negative for HbsAg but positive for HBcAb (regardless of HBsAb status), HBV DNA testing is also required. If HBV DNA \<10³ IU/ml, the patient may be enrolled. If the patient tests positive for HCV antibody, HCV RNA is detected by PCR. If positive, the patient meets the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2 years Progression free survival (2Y-PFS) | up to 2 years | PFS is defined as the time from registration to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause. PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | up to 8 months | ORR is defined as the proportion of patients with a response of CR or PR |
| Complete Response Rate (CR) | up to 8 months | The rate of patients who achieved complete response after treatment |
| overall survival (OS) | up to 3 years | Overall survival is defined as the period from the induction registration to death from any cause. Patients who have not died until the time of the analysis will be censored at their last contact date. |
Countries
China
Contacts
Primary Contacthui Liu
Outcome results
None listed